nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

10.02.2016 | Review

Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy

verfasst von: Ioannis Kyriakidis, Paraskevi Papaioannidou

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Ovarian cancer remains the leading cause of mortality due to gynecological tumors. Estrogen receptors (ERs) seem to participate in tumor progression even in the absence of estrogens. Twenty years after the cloning of the second estrogen receptor, a wide spectrum of studies have shown its implication in both physiologic and pathologic pathways. ERβ, being the predominant type of ER in normal ovary tissue, has not only been linked with pathogenesis of ovarian cancer, but also with response to treatment. Unlike ERα, which is primarily linked with cell growth, ERβ presence is prominent in signaling pathways, cell cycle regulation and apoptosis.

Methods

Literature review of relevant published material (from PubMed, Scopus, and Cochrane databases) was conducted.

Results

Polymorphisms in the respective ESR2 gene, epigenetic modifications and isoforms of the receptor have been extensively studied to assess potential correlations with responsiveness to treatment and tumor behavior. Studies on the exact roles of ERβ and its genetic variations in altering effectiveness and toxicity of ovarian cancer treatment regimens are lacking.

Conclusion

Clinical utilization of ERβ actions in the management of ovarian cancer is discussed in an up-to-date review.

Jia M, Dahlman-Wright K, Gustafsson JÅ (2015) Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab 29(4):557–568. doi:10.1016/j.beem.2015.04.008 CrossRefPubMed

Imamov O, Shim GJ, Warner M, Gustafsson JA (2005) Estrogen receptor beta in health and disease. Biol Reprod 73(5):866–871CrossRefPubMed

Heldring N, Pike A, Andersson S et al (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87(3):905–931CrossRefPubMed

Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116(3):561–570CrossRefPubMedPubMedCentral

Zhao C, Dahlman-Wright K, Gustafsson JA (2008) Estrogen receptor beta: an overview and update. Nucl Recept Signal 6:e003. doi:10.1621/nrs.06003 PubMedPubMedCentral

Ciucci A, Zannoni GF, Travaglia D, Scambia G, Gallo D (2015) Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer. Hum Pathol 46(8):1138–1146. doi:10.1016/j.humpath.2015.03.016 CrossRefPubMed

Drummond AE, Fuller PJ (2010) The importance of ERbeta signalling in the ovary. J Endocrinol 205(1):15–23. doi:10.1677/JOE-09-0379 CrossRefPubMed

Nott SL, Huang Y, Fluharty BR et al (2008) Do estrogen receptor beta polymorphisms play a role in the pharmacogenetics of estrogen signaling? Curr Pharmacogenom Person Med 6(4):239–259CrossRef

Lee HR, Kim TH, Choi KC (2012) Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse. Lab Anim Res 28(2):71–76. doi:10.5625/lar.2012.28.2.71 CrossRefPubMedPubMedCentral

10.

Bossard C, Busson M, Vindrieux D et al (2012) Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One 7(9):e44787. doi:10.1371/journal.pone.0044787 CrossRefPubMedPubMedCentral

11.

Lazennec G (2006) Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 231(2):151–157CrossRefPubMedPubMedCentral

12.

Docquier A, Garcia A, Savatier J et al (2013) Negative regulation of estrogen signaling by ERβ and RIP140 in ovarian cancer cells. Mol Endocrinol 27(9):1429–1441. doi:10.1210/me.2012-1351 CrossRefPubMed

13.

Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193(3):421–433CrossRefPubMed

14.

Fekete T, Rásó E, Pete I et al (2012) Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int J Cancer 131(1):95–105. doi:10.1002/ijc.26364 CrossRefPubMed

15.

Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11(3):537–551CrossRefPubMedPubMedCentral

16.

Rutherford T, Brown WD, Sapi E, Aschkenazi S, Muñoz A, Mor G (2000) Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol 96(3):417–421PubMed

17.

Mendoza N, Morón FJ, Quereda F et al (2008) A digenic combination of polymorphisms within ESR1 and ESR2 genes are associated with age at menarche in the Spanish population. Reprod Sci 15(3):305–311. doi:10.1177/1933719107314064 CrossRefPubMed

18.

Mendoza N, Sánchez-Borrego R, Galiano D et al (2009) Multigenic combination of estrogen-related genes is associated with age at natural menopause in a Spanish population. Menopause Int 15(4):150–156. doi:10.1258/mi.2009.009043 PubMed

19.

Lau KM, Mok SC, Ho SM (1999) Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96(10):5722–5727CrossRefPubMedPubMedCentral

20.

Li AJ, Baldwin RL, Karlan BY (2003) Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 189(1):22–27CrossRefPubMed

21.

Aust S, Horak P, Pils D et al (2013) The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC Cancer 13:115. doi:10.1186/1471-2407-13-115 CrossRefPubMedPubMedCentral

22.

Ciucci A, Zannoni GF, Travaglia D, Petrillo M, Scambia G, Gallo D (2014) Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer. Gynecol Oncol 132(2):351–359. doi:10.1016/j.ygyno.2013.12.027 CrossRefPubMed

23.

De Stefano I, Zannoni GF, Prisco MG et al (2011) Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol 122(3):573–579. doi:10.1016/j.ygyno.2011.05.025 CrossRefPubMed

24.

Hu Z, Zhu L, Tan M et al (2015) The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer. Biochimie 109:42–48. doi:10.1016/j.biochi.2014.12.001 CrossRefPubMed

25.

Burges A, Brüning A, Dannenmann C et al (2010) Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 281(3):511–517. doi:10.1007/s00404-009-1185-y CrossRefPubMed

26.

Lenhard M, Tereza L, Heublein S et al (2012) Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer 12:553. doi:10.1186/1471-2407-12-553 CrossRefPubMedPubMedCentral

27.

Fujimoto J, Hirose R, Sakaguchi H, Tamaya T (2000) Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers. Oncology 58(4):334–341. doi:10.1159/000012121 CrossRefPubMed

28.

van Kruchten M, van der Marel P, de Munck L et al (2015) Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol 138(3):634–639. doi:10.1016/j.ygyno.2015.06.032 CrossRefPubMed

29.

Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY (2008) Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 111(1):144–151. doi:10.1097/01.AOG.0000296715.07705.e9 CrossRefPubMed

30.

Jönsson JM, Skovbjerg Arildsen N, Malander S et al (2015) Sex steroid hormone receptor expression affects ovarian cancer survival. Transl Oncol 8(5):424–433. doi:10.1016/j.tranon.2015.09.002 CrossRefPubMedPubMedCentral

31.

Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J (2013) Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 23(1):25–33. doi:10.1097/IGC.0b013e3182788466 CrossRefPubMed

32.

de Toledo MC, Sarian LO, Sallum LF et al (2014) Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the “triple-negative” tumor status to disease-free and overall survival of women with epithelial ovarian cancer. Acta Histochem 116(3):440–447. doi:10.1016/j.acthis.2013.09.010 CrossRefPubMed

33.

Fuller PJ, Chu S (2004) Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab 15(3):122–128CrossRefPubMed

34.

Alexiadis M, Eriksson N, Jamieson S et al (2011) Nuclear receptor profiling of ovarian granulosa cell tumors. Horm Cancer 2(3):157–169. doi:10.1007/s12672-011-0069-3

35.

Hutton SM, Webster LR, Nielsen S, Leung Y, Stewart CJ (2012) Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary. Pathology 44(7):611–616. doi:10.1097/PAT.0b013e328359d636 CrossRefPubMed

36.

Figtree GA, Noonan JE, Bhindi R, Collins P (2009) Estrogen receptor polymorphisms: significance to human physiology, disease and therapy. Recent Pat DNA Gene Seq 3(3):164–171CrossRefPubMed

37.

Lurie G, Wilkens LR, Thompson PJ et al (2009) Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma. Cancer Causes Control 20(1):47–55. doi:10.1007/s10552-008-9216-8 CrossRefPubMedPubMedCentral

38.

Ryan J, Canonico M, Carcaillon L et al (2012) Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. PLoS One 7(3):e34112. doi:10.1371/journal.pone.0034112 CrossRefPubMedPubMedCentral

39.

Dai ZJ, Wang BF, Ma YF et al (2014) Current evidence on the relationship between rs1256049 polymorphism in estrogen receptor-β gene and cancer risk. Int J Clin Exp Med 7(12):5031–5040PubMedPubMedCentral

40.

Leigh Pearce C, Near AM, Butler JL et al (2008) Comprehensive evaluation of ESR2 variation and ovarian cancer risk. Cancer Epidemiol Biomark Prev 17(2):393–396. doi:10.1158/1055-9965.EPI-07-2512 CrossRef

41.

Pearce CL, Near AM, Van Den Berg DJ, Australian Cancer Study, Australian Ovarian Cancer Study Group et al (2009) Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer 100(2):412–420. doi:10.1038/sj.bjc.6604820

42.

Delort L, Chalabi N, Satih S et al (2008) Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res 28(5B):3079–3081PubMed

43.

Philips S, Richter A, Oesterreich S et al (2012) Functional characterization of a genetic polymorphism in the promoter of the ESR2 gene. Horm Cancer 3(1–2):37–43. doi:10.1007/s12672-011-0086-2 CrossRefPubMedPubMedCentral

44.

Schüler S, Lattrich C, Skrzypczak M, Fehm T, Ortmann O, Treeck O (2014) Polymorphisms in the promoter region of ESR2 gene and susceptibility to ovarian cancer. Gene 546(2):283–287. doi:10.1016/j.gene.2014.05.066 CrossRefPubMed

45.

Lurie G, Wilkens LR, Thompson PJ, Goodman MT et al (2011) Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. PLoS One 6(6):20703. doi:10.1371/journal.pone.0020703 CrossRef

46.

Goulart AC, Zee RY, Rexrode KM (2009) Association of estrogen receptor 2 gene polymorphisms with obesity in women (obesity and estrogen receptor 2 gene). Maturitas 62(2):179–183. doi:10.1016/j.maturitas.2008.11.006 CrossRefPubMedPubMedCentral

47.

Nilsson M, Dahlman I, Jiao H et al (2007) Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis—a cohort study. BMC Med Genet 8:73CrossRefPubMedPubMedCentral

48.

Suzuki F, Akahira J, Miura I et al (2008) Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5′-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 99(12):2365–2372. doi:10.1111/j.1349-7006.2008.00988.x CrossRefPubMed

49.

Yap OW, Bhat G, Liu L, Tollefsbol TO (2009) Epigenetic modifications of the estrogen receptor beta gene in epithelial ovarian cancer cells. Anticancer Res 29(1):139–144PubMedPubMedCentral

50.

Al-Nakhle H, Smith L, Bell SM et al (2013) Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5′ regulatory region. Int J Oncol 43(6):2039–2045. doi:10.3892/ijo.2013.2112 PubMed

51.

Al-Nakhle H, Burns PA, Cummings M et al (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70(11):4778–4784. doi:10.1158/0008-5472.CAN-09-4104 CrossRefPubMedPubMedCentral

52.

Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J (2014) The many faces of estrogen signaling. Biochem Med (Zagreb) 24(3):329–342. doi:10.11613/BM.2014.035 CrossRef

53.

Yamaguchi K, Matsumura N, Mandai M, Baba T, Konishi I, Murphy SK (2014) Epigenetic and genetic dispositions of ovarian carcinomas. Oncoscience 1(9):574–579CrossRefPubMedPubMedCentral

54.

Yamaguchi K, Huang Z, Matsumura N et al (2014) Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer 135(3):585–597. doi:10.1002/ijc.28701 CrossRefPubMedPubMedCentral

55.

Alves LN, Wolfgramm EV, de Castro Neto AK, Louro ID (2013) Analysis of microsatellite instability and loss of heterozygosity in ovarian cancer: a study in the population of Espírito Santo, Brazil. Genet Mol Res 12(2):1996–2001. doi:10.4238/2013.June.14.2 CrossRefPubMed

56.

Pitta CA, Papageorgis P, Charalambous C, Constantinou AI (2013) Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance. Cancer Lett 337(2):167–176. doi:10.1016/j.canlet.2013.05.031 CrossRefPubMed

57.

Koukoura O, Spandidos DA, Daponte A, Sifakis S (2014) DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (review). Mol Med Rep 10(1):3–9. doi:10.3892/mmr.2014.2221 PubMedPubMedCentral

58.

Meng F, Sun G, Zhong M, Yu Y, Brewer MA (2013) Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer. Br J Cancer 108(3):579–586. doi:10.1038/bjc.2013.10 CrossRefPubMedPubMedCentral

59.

Kovats S (2015) Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol 294(2):63–69. doi:10.1016/j.cellimm.2015.01.018 CrossRefPubMedPubMedCentral

60.

Stellato C, Porreca I, Cuomo D, Tarallo R, Nassa G, Ambrosino C (2015) The “busy life” of unliganded estrogen receptors. Proteomics. doi:10.1002/pmic.201500261

61.

Martinez-Arguelles DB, Papadopoulos V (2010) Epigenetic regulation of the expression of genes involved in steroid hormone biosynthesis and action. Steroids 75(7):467–476. doi:10.1016/j.steroids.2010.02.004 CrossRefPubMedPubMedCentral

62.

Zama AM, Uzumcu M (2009) Fetal and neonatal exposure to the endocrine disruptor methoxychlor causes epigenetic alterations in adult ovarian genes. Endocrinology 150(10):4681–4691. doi:10.1210/en.2009-0499 CrossRefPubMedPubMedCentral

63.

Karmaus W, Osuch JR, Landgraf J, Taffe B, Mikucki D, Haan P (2011) Prenatal and concurrent exposure to halogenated organic compounds and gene expression of CYP17A1, CYP19A1, and oestrogen receptor alpha and beta genes. Occup Environ Med 68(6):430–437. doi:10.1136/oem.2009.053249 CrossRefPubMed

64.

Mahmoud AM, Al-Alem U, Ali MM, Bosland MC (2015) Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation. J Steroid Biochem Mol Biol 152:62–75. doi:10.1016/j.jsbmb.2015.04.018 CrossRefPubMed

65.

Darabi M, Ani M, Panjehpour M, Rabbani M, Movahedian A, Zarean E (2011) Effect of estrogen receptor β A1730G polymorphism on ABCA1 gene expression response to postmenopausal hormone replacement therapy. Genet Test Mol Biomark 15(1–2):11–15. doi:10.1089/gtmb.2010.0106 CrossRef

66.

Halon A, Nowak-Markwitz E, Maciejczyk A et al (2011) Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res 31(2):711–718PubMed

67.

Pons DG, Sastre-Serra J, Nadal-Serrano M et al (2012) Initial activation status of the antioxidant response determines sensitivity to carboplatin/paclitaxel treatment of ovarian cancer. Anticancer Res 32(11):4723–4728PubMed

68.

Marsh S (2009) Pharmacogenomics of taxane/platinum therapy in ovarian cancer. Int J Gynecol Cancer 19(Suppl 2):S30–S34. doi:10.1111/IGC.0b013e3181c10513 CrossRefPubMed

69.

Pawlik A, Dziedziejko V, Kurzawski M, Safranow K, Kotrych D, Bohatyrewicz A (2012) Effect of ESR1 and ESR2 gene polymorphisms on rheumatoid arthritis treatment with methotrexate. Pharmacol Rep 64(1):185–190CrossRefPubMed

70.

Dziedziejko V, Kurzawski M, Safranow K, Chlubek D, Pawlik A (2011) The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 12(1):41–47. doi:10.2217/pgs.10.164 CrossRefPubMed

71.

Henry NL, Nguyen A, Azzouz F et al (2010) Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer 102(2):294–300. doi:10.1038/sj.bjc.6605460 CrossRefPubMedPubMedCentral

72.

Jin Y, Hayes DF, Li L et al (2008) Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 26(36):5849–5854. doi:10.1200/JCO.2008.16.8377 CrossRefPubMedPubMedCentral

73.

Ribeiro JR, Freiman RN (2014) Estrogen signaling crosstalk: implications for endocrine resistance in ovarian cancer. J Steroid Biochem Mol Biol 143:160–173. doi:10.1016/j.jsbmb.2014.02.010 CrossRefPubMed

74.

National Center for Biotechnology Information, US National Library of Medicine (2015). http://www.ncbi.nlm.nih.gov/projects/SNP/. Accessed 7 Nov 2015

Titel: Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy
verfasst von: Ioannis Kyriakidis
Paraskevi Papaioannidou
Publikationsdatum: 10.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 6/2016
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-016-4027-8

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy

Abstract

Introduction

Methods

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

F-18 fluoro-d-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in planning of surgery and sentinel lymph node screening in vulvar cancers

Evaluation of preventive effect of shilajit on radiation-induced apoptosis on ovaries

Pelvic floor muscle training for female urinary incontinence: Does it work?

Author reply: No immediate increase in morbidity of infants delivered by term cesarean section for placenta previa: some concerns

The challenge of preoperative identification of uterine myomas: Is ultrasound trustworthy? A prospective cohort study

Serum vitamin D status and in vitro fertilization outcomes: a systematic review and meta-analysis

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie